News Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Real-time Estimate Cboe BZX Other stock markets 10:29:05 2024-05-16 am EDT			5-day change	1st Jan Change
9.585 ^USD	-0.88%		-1.07%	-43.31%

May. 14	Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	MT
May. 14	Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression	May. 14	MT
Neumora Therapeutics Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	May. 14	AQ
Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression	May. 14	CI
Neumora Therapeutics Shares Fall as Q1 Loss Narrows	May. 07	MT
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	May. 07	AQ
Neumora Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
Neumora Therapeutics to Participate in Upcoming Conferences in May	May. 06	AQ
Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 15	MT
Sector Update: Health Care	Apr. 15	MT
Investors Shrug Off Geopolitical Concerns, Driving Premarket Gains for US Equity Futures	Apr. 15	MT
Upcoming Earnings Buoy Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday	Apr. 15	MT
Top Premarket Decliners	Apr. 15	MT
Neumora Therapeutics' Phase 1 Trial of Potential Brain Disease Drug on Hold After Convulsions in Rabbits	Apr. 15	MT
Neumora Shares Slide Premarket as FDA Puts Early Study of Schizophrenia Drug on Hold	Apr. 15	DJ
Neumora's early-stage schizophrenia drug study put on hold	Apr. 15	RE
U.S. FDA places clinical hold on Neumora's schizophrenia drug study	Apr. 15	RE
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study	Apr. 15	AQ
Neumora Therapeutics Announces Clinical Hold of Phase 1 NMRA-266 Study	Apr. 15	CI
JPMorgan Adjusts Price Target on Neumora Therapeutics to $22 From $20, Maintains Overweight Rating	Mar. 18	MT
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to S&P Global BMI Index	Mar. 17	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Neumora Therapeutics, Inc.

Equities

NMRA

US6409791000

Summary

Filters